Healthcare Industry News: NPWT
News Release - February 7, 2012
Lyndon B. Johnson General Hospital First to use PICO* Single Use Negative Pressure Wound Therapy System from Smith & NephewST. PETERSBURG, Fla., Feb. 7, 2012 -- (Healthcare Sales & Marketing Network) -- Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business, announces the first use in the United States of the pocket-sized PICO single use Negative Pressure Wound Therapy (NPWT) System. Sonya Ahmed, MD, Department of Orthopaedic Surgery at Lyndon B. Johnson General Hospital and Assistant Professor in the Department of Orthopaedic Surgery at The University of Texas Health Science Center at Houston (UTHealth) Medical School, applied the PICO system to a patient's incision following surgery to repair his calcaneal fracture, or fracture of the heel bone. The PICO system just received FDA clearance for commercial use in the U.S. Smith & Nephew will exhibit PICO at the American Academy of Orthopedic Surgeons' annual meeting in San Francisco.
The patient's injury was a result of a high energy fall from a height. After the surgery to repair the fracture, Dr. Ahmed applied the new PICO system to the closed surgical wound.
"This type of post-surgical wound is often complicated by co-morbidities such as diabetes, smoking, obesity and surrounding vascularity," Dr. Ahmed said. "Early findings have revealed that NPWT creates an environment that may support less wound complications in these cases, and when used correctly may reduce long-term complications. During my first experience with PICO, I removed the system after 72 hours. The incision was pristine. There were no signs of ischemia, drainage or desquamation to the surrounding skin or incision. After one-week follow-up I am pleased with the appearance of this wound and am anxious to obtain long-term results."
"At LBJ, we aim to provide great medical care in a safe, compassionate, and cost-conscious manner," said Jessie L. Tucker III, PhD, Senior Vice President and Administrator of Lyndon B. Johnson General Hospital. "So we are quick to adopt innovative technologies that enable us to enhance patient care effectively and efficiently. We are proud to have had the first case with PICO in the U.S."
In addition to the traditional indications for NPWT, the PICO system is indicated for closed surgical incisions. This use of NPWT expands the application of NPWT to include patients recovering from orthopaedic, plastic and general surgeries, to help reduce surgical site complications in high-risk patients or those undergoing high-risk procedures. There are 28 million surgical incisions in the U.S. annually, 10% to 15% of which are considered high risk.
With its palm sized, one-button pump and revolutionary dressing technology that manages fluids without a bulky canister, the PICO system represents an entirely new way to deliver NPWT and a significant advancement for the patient, clinician and payer: It brings NPWT to a wider range of patients. Its simplicity and ease of use enables more clinicians to use NPWT in a cost-effective manner. For the payer, the PICO system is more affordable and can significantly reduce therapy costs associated with traditional NPWT as it is available off-the-shelf, helping to conserve and manage healthcare resources.
"LBJ Hospital aims to provide the highest quality care within tight economic limits," said Thomas Dugan, President, Smith & Nephew Advanced Wound Management, North America. "Smith & Nephew is committed to innovation that reduces the human and economic costs of wounds. Reflecting this commitment, we built our PICO system to help clinicians make NPWT available to a broader range of patients at a lower cost. We are delighted to have supported Dr. Ahmed and LBJ Hospital in this way and we are excited by the rapid and enthusiastic adoption we are seeing in hospitals across the U.S."
Participating clinicians can see the PICO system in the Smith & Nephew Booth #4947 at AAOS 2012 in San Francisco, from February 7--11, 2012. More information is available at the PICO system's mobile compatible website, www.possiblewithpico.com. Please follow @woundcare on Twitter for the latest news from the Advanced Wound Management division of Smith & Nephew. Clinicians and patients may also refer to the 24/7 negative pressure wound therapy hotline, 866-998-NPWT (6798), for more information about the NPWT portfolio of products from Smith & Nephew.
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine, Trauma and Clinical Therapies, Smith & Nephew has almost 11,000 employees and a presence in more than 90 countries. Annual sales in 2011 were nearly $4.3 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payors and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions and our success in integrating acquired businesses; and numerous other matters that affect us or our markets, including those of a political, economic, business or competitive nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors.
Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.
*Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.
Source: Smith & Nephew
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsSmith & Nephew to expand Real Intelligence digital ecosystem and CORI(TM) Surgical System with total hip arthroplasty
Smith & Nephew launches new total ankle and total shoulder replacement technologies; showcases recently acquired Extremity Orthopaedics portfolio at AAOS
New data underscores material benefits of Smith & Nephew's OXINIUM(TM) DH Technology and OR3O(TM) Dual Mobility System for total hip arthroplasty versus Cobalt Chrome liners